Histone Methyltransferase

Histone modifications play critical roles in regulating both global and stage-specific gene expression. Methylation on histones H3K4, H3K36 and H3K79 is generally associated with gene activation, whereas methylation on histones H3K9 and H3K27 is generally associated with gene repression. Histone lysine methylation is dynamically regulated by site-specific methyltransferases and demethylases. EZH2 (the catalytic subunit of PRC2) is responsible for the methylation of H3K27 in cells.

DOT1L is a histone H3 lysine 79 methyltransferase whose inhibition increases the yield of induced pluripotent stem cells (iPSCs). EPZ-5676 is a potent and selective DOT1L inhibitor.

Crucial to PRC2 activity, the histone methyltransferase enhancer of zeste homolog 2 (EZH2) tri-methylates lysine 27 of histone 3 (H3K27me3), leading to chromatin condensation and transcriptional repression.

(R)-HH2853

Cat. No.: HY-144882

(R)-HH2853 is a **mutant EZH2** inhibitor with an IC_{50} of <100 nM for **EZH2-Y641F**. (R)-HH2853 can be used for cancer and autoimmune diseases (WO2018045971A1; compound 201).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(S)-HH2853

Cat. No.: HY-144881

(S)-HH2853 (compound 200), a PYRIDINO five membered aromatic ring compound, is a potent **EZH1/2** dual inhibitor with an IC_{50} of <100 nM for EZH2_Y641F. (S)-HH2853 has the potential to be used in the research of anti-tumor or autoimmune diseases.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

3-Deazaneplanocin A

(DZNep; 3-Deazaneplanocin) Cat. No.: HY-10442

3-Deazaneplanocin A (DZNep) is a potent **histone methyltransferase EZH2** inhibitor. 3-Deazaneplanocin A is a potent **S-adenosylhomocysteine hydrolase (AHCY)** inhibitor.



Purity: 98.12%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

3-Deazaneplanocin A hydrochloride (DZNep hydrochloride; NSC 617989 hydrochloride; 3-Deazaneplanocin hydrochloride)

Cat. No.: HY-12186

3-Deazaneplanocin A hydrochloride (DZNep hydrochloride) is a potent **histone methyltransferase EZH2** inhibitor. 3-Deazaneplanocin A hydrochlorideis a potent **S-adenosylhomocysteine hydrolase (AHCY)** inhibitor.



Purity: 99.98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg

A-196

Cat. No.: HY-100201

A-196 is a potent and selective inhibitor of **SUV420H1** and **SUV420H2** with IC_{50} values of 25 nM and 144 nM, respectively. A-196 inhibits **SUV4-20** biochemically in a substrate-competitive manner.



Purity: 99.73%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

A-366

Cat. No.: HY-12583

A-366 is a potent, highly selective, peptide-competitive histone methyltransferase **G9a** inhibitor with IC_{50}s of 3.3 and 38 nM for G9a and GLP (EHMT1), respectively. A-366 shows >1000-fold selectivity over 21 other methyltransferases.



Purity: 98.02%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

A-395

Cat. No.: HY-101512

A-395 is an antagonist of **polycomb repressive complex 2 (PRC2)** protein-protein interactions that potently inhibits the trimeric PRC2 complex (EZH2-EED-SUZ12) with an IC_{50} of 18 nM.



Purity: 99.31%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

A-893

Cat. No.: HY-19563

A-893 is a cell-active inhibitor of Methyltransferase **SMYD2**, with an IC_{50} of 2.8 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AMI-1

Cat. No.: HY-18962

AMI-1 is a potent, cell-permeable and reversible inhibitor of **protein arginine N-methyltransferases (PRMTs)**, with IC_{50}s of 8.8 μM and 3.0 μM for human PRMT1 and yeast-Hmt1p, respectively. AMI-1 exerts PRMTs inhibitory effects by blocking peptide-substrate binding.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

AMI-1 free acid

Cat. No.: HY-18962A

AMI-1 free acid is a potent, cell-permeable and reversible inhibitor of **protein arginine N-methyltransferases (PRMTs)**, with IC_{50}s of 8.8 μM and 3.0 μM for human PRMT1 and yeast-Hmt1p, respectively.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 25 mg

Amodiaquine

(Amodiaquin) Cat. No.: HY-B1322A

Amodiaquine (Amodiaquin), a 4-aminoquinoline class of antimalarial agent, is a potent and orally active **histamine N-methyltransferase** inhibitor.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Amodiaquine dihydrochloride

(Amodiaquin dihydrochloride) Cat. No.: HY-B1322B

Amodiaquine dihydrochloride (Amodiaquin dihydrochloride), a 4-aminoquinoline class of antimalarial agent, is a potent and orally active **histamine N-methyltransferase** inhibitor with a K_i of 18.6 nM.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

Amodiaquine dihydrochloride dihydrate

(Amodiaquin dihydrochloride dihydrate) Cat. No.: HY-B1322

Amodiaquine dihydrochloride dihydrate (Amodiaquin dihydrochloride dihydrate), a 4-aminoquinoline class of antimalarial agent, is a potent and orally active **histamine N-methyltransferase** inhibitor.



Purity: 99.73%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

Amodiaquine-d10

Cat. No.: HY-B1322AS

Amodiaquine-d10 is the deuterium labeled Amodiaquine. Amodiaquine (Amodiaquin), a 4-aminoquinoline class of antimalarial agent, is a potent and orally active **histamine N-methyltransferase** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 10 mg

AS-85

Cat. No.: HY-141430

AS-85 is a potent **ASH1L histone methyltransferase** inhibitor (IC_{50}=0.6 μM) with anti-leukemic activity. AS-85 strongly binds to the ASH1L SET domain, with the K_d value of 0.78μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AS-99

Cat. No.: HY-141429C

AS-99 is a first-in-class, potent, and selective **ASH1L histone methyltransferase** inhibitor (IC_{50}=0.79μM, K_d=0.89μM) with anti-leukemic activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AS-99 free base

Cat. No.: HY-141429

AS-99 is a first-in-class, potent and selective **ASH1L histone methyltransferase** inhibitor (IC_{50}=0.79μM, K_d=0.89μM) with anti-leukemic activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

AS-99 TFA

Cat. No.: HY-141429A

AS-99 TFA is a first-in-class, potent and selective **ASH1L histone methyltransferase** inhibitor (IC_{50}=0.79μM, K_d=0.89μM) with anti-leukemic activity.



Purity: 98.89%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

AZ505

Cat. No.: HY-15226

AZ505 is a potent and selective **SMYD2** inhibitor with an IC_{50} of 0.12 μM.



Purity: 99.99%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

AZ505 ditrifluoroacetate

Cat. No.: HY-15226A

AZ505 ditrifluoroacetate is a potent and selective **SMYD2** inhibitor with IC_{50} of 0.12 μM.



Purity: 99.99%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

AZ506

Cat. No.: HY-134828

AZ506 is a potent **SMYD2** inhibitor with an IC_{50} of 17 nM. AZ506 inhibits SMYD2 methyltransferase activity in cells, leading to a decrease in the SMYD2-mediated methylation signal.



Purity: 99.74%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

BAY-598

Cat. No.: HY-19546

BAY-598 is selective small molecule inhibitor of **SMYD2** with an IC_{50} of 27 nM.



Purity: 99.91%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

BAY-6035

Cat. No.: HY-112080

BAY-6035 is a potent, selective and substrate-competitive inhibitor of **SMYD3**. BAY-6035 inhibits methylation of MEKK2 peptide with an IC_{50} of 88 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BCI-121

Cat. No.: HY-21972

BCI-121 is a **SMYD3** inhibitor that impairs the proliferation of cancer cell.



Purity: 99.45%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

BI-9321

Cat. No.: HY-114208

BI-9321 is a potent, selective and cellular active **nuclear receptor-binding SET domain 3 (NSD3)-PWWP1 domain** antagonist with a K_d value of 166 nM. BI-9321 is inactive against NSD2-PWWP1 and NSD3-PWWP2.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BI-9321 trihydrochloride

Cat. No.: HY-114208A

BI-9321 trihydrochloride is a potent, selective and cellular active **nuclear receptor-binding SET domain 3 (NSD3)-PWWP1 domain** antagonist with a K_d value of 166 nM. BI-9321 trihydrochloride is inactive against NSD2-PWWP1 and NSD3-PWWP2.



Purity: 98.89%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

BIX-01294

Cat. No.: HY-10587

BIX-01294 is a reversible and highly selective **G9a and GLP Histone Methyltransferase** inhibitor, with IC_{50}s of of 1.7 μM and 0.9 μM, respectively.



Purity: 99.59%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

BIX-01294 trihydrochloride

Cat. No.: HY-108239

BIX-01294 trihydrochloride is a reversible and highly selective **G9a and GLP Histone Methyltransferase** inhibitor, with IC_{50}s of of 1.7 μM and 0.9 μM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BIX-01338 hydrate

(BIX01338 hydrate; BIX 01338 hydrate)

Cat. No.: HY-12991A

BIX-01338 hydrate is a **histone lysine methyltransferase** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BRD0639

Cat. No.: HY-132309

BRD0639 is a first-in-class inhibitor of the **PRMT5-substrate adaptor interaction**. BRD0639 is a PRMT5 binding motif (PBM)-competitive agent that can support studies of PBM dependent PRMT5 activities.



Purity: 99.17%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

BRD4770

Cat. No.: HY-16705

BRD4770 is a **histone methyltransferase G9a** inhibitor. BRD4770 reduces di- and trimethylation of **lysine 9 on histone H3 (H3K9)** with an EC_{50} of 5 μM, and has less or little effect toward H3K27me3, H3K36me3, H3K4me3, and H3K79me3.



Purity: 99.77%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 500 mg

BRD9539

Cat. No.: HY-15647

BRD9539 is a **histone methyltransferase G9a** inhibitor with an IC_{50} of 6.3 μM. BRD9539 also inhibits **PRC2** activity and is inactive against SUV39H1, NSD2 and DNMT1.



Purity: 99.20%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

BVT948

Cat. No.: HY-100625

BVT948 is a **protein tyrosine phosphatase** (**PTP**) inhibitor which can also inhibit several **cytochrome P450** (**P450**) isoforms and lysine methyltransferase **SETD8** (**KMT5A**).



Purity: 98.66%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg

C-7280948

Cat. No.: HY-15890

C-7280948 is a selective and potent protein **methyltransferase1 (PRMT1)** inhibitor with an IC_{50} value of 12.75 μM.



Purity: 98.31%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

CARM1-IN-1

Cat. No.: HY-12759

CARM1-IN-1 is a potent and specific CARM1(Coactivator-associated arginine methyltransferase 1) inhibitor with IC50 of 8.6 uM; shows very low activity against PRMT1 and SET7(IC50 > 600 uM).



Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

CARM1-IN-1 hydrochloride

Cat. No.: HY-12759A

CARM1-IN-1 hydrochloride is a potent and specific CARM1(Coactivator-associated arginine methyltransferase 1) inhibitor with IC50 of 8.6 uM; shows very low activity against PRMT1 and SET7(IC50 > 600 uM).



Purity: 95.16%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg

Chaetocin

Cat. No.: HY-N2019

Chaetocin is a specific inhibitor of the histone methyltransferase (**HMT**) SU(VAR)3-9 with an IC_{50} of 0.6 μM for SU(VAR)3-9. It also inhibits thioredoxin reductase (**TrxR**) with an IC_{50} of 4 μM.



Purity: 99.95%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

CM-272

Cat. No.: HY-101925

CM-272 is a first-in-class, potent, selective, substrate-competitive and reversible dual **G9a/DNA methyltransferases (DNMTs)** inhibitor with antitumor activities.



Purity: 99.27%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

CM-579

Cat. No.: HY-117421

CM-579 is a first-in-class reversible, dual inhibitor of **G9a** and **DNMT**, with IC_{50} values of 16 nM, 32 nM for G9a and DNMT, respectively. Has potent in vitro cellular activity in a wide range of cancer cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CM-579 trihydrochloride

Cat. No.: HY-117421A

CM-579 trihydrochloride is a first-in-class reversible, dual inhibitor of **G9a** and **DNMT**, with IC_{50} values of 16 nM, 32 nM for G9a and DNMT, respectively. Has potent in vitro cellular activity in a wide range of cancer cells.



Purity: 98.03%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

CMP-5

Cat. No.: HY-120137

CMP-5 is a potent, specific, and selective **PRMT5** inhibitor, while displays no activity against PRMT1, PRMT4, and PRMT7 enzymes. CMP-5 selectively blocks S2Me-H4R3 by inhibiting PRMT5 methyltransferase activity on histone preparations.



Purity: 98.69%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

CMP-5 hydrochloride

Cat. No.: HY-113846

CMP-5 hydrochloride is a potent, specific, and selective **PRMT5** inhibitor, while displays no activity against PRMT1, PRMT4, and PRMT7 enzymes. CMP-5 hydrochloride selectively blocks S2Me-H4R3 by inhibiting PRMT5 methyltransferase activity on histone preparations.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CPI-1328

Cat. No.: HY-134899

CPI-1328 is an **EZH2** inhibitor with a K_i value of 63 fM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CPI-169

(CPI 169 R-enantiomer)

Cat. No.: HY-15956A

CPI-169 (CPI 169 R-enantiomer) is a novel and potent **EZH2** inhibitor, with IC_{50}s of 0.24 nM, 0.51 nM, and 6.1 nM for EZH2 WT, EZH2 Y641N, and EZH1, respectively.



Purity: 98.17%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

CPI-360

Cat. No.: HY-15955

CPI-360 is a potent, selective EZH2inhibitor with IC50 of 0.5 nM and 2.5 nM nM for wt EZH2 and Y641N EZH2, respectively.



Purity: 99.43%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

CPUY074020

Cat. No.: HY-100757

CPUY074020 is a potent and oral bioavailable inhibitor of histone methyltransferase **G9a**, with an IC_{50} of 2.18 μM. CPUY074020 possesses anti-proliferative activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CSV0C018875

Cat. No.: HY-133031

CSV0C018875 is a quinoline-based **EHMT2/G9a** inhibitor. CSV0C018875 exhibits lesser cytotoxicity than BIX-01294.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

DCLX069

Cat. No.: HY-122096

DCLX069 is a selective **protein arginine methyltransferase 1 (PRMT1)** inhibitor with an IC_{50} value of 17.9 μM. DCLX069 shows less active against PRMT4 and PRMT6. DCLX069 has anticancer effects.



Purity: 98.38%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

DC_C66

Cat. No.: HY-100855

DC_C66 is a cell-permeable, selective **coactivator associated arginine methyltransferase 1 (CARM1)** inhibitor with an IC_{50} of 1.8 μM. DC_C66 has a good selectivity for CARM1 against PRMT1 (IC_{50}=21 μM), PRMT6 (IC_{50}= 47μM), and PRMT5.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

DDO-2093

Cat. No.: HY-132233

DDO-2093 is a potent **MLL1-WDR5 protein-protein interaction** inhibitor (IC_{50}=8.6 nM; K_d=11.6 nM) with antitumor activity. DDO-2093 selectively inhibits the catalytic activity of MLL complex.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

DM-01

Cat. No.: HY-131246

DM-01 is a powerful and selective **EZH2** inhibitor for the research of diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and SNF5/INI-1/SMARCB1 genetically defined solid tumors.



Purity: 98.03%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Dot1L-IN-1

Cat. No.: HY-101520

Dot1L-IN-1 is a highly potent, selective and structurally novel **Dot1L** inhibitor with a K_i of 2 pM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Dot1L-IN-2

Cat. No.: HY-111390

Dot1L-IN-2 is a potent, selective and orally bioavailable inhibitor of **Dot1L** (a **histone methyltransferase**), with an IC_{50} and K_i of 0.4 nM and 0.08 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Dot1L-IN-4

Cat. No.: HY-135127

Dot1L-IN-4 is a potent disruptor of telomeric silencing 1-like protein (**DOT1L**) inhibitor with an $IC_{50\ SPA\ DOT1L}$ of 0.11 nM.



Purity: 99.60%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Dot1L-IN-5

Cat. No.: HY-135128

Dot1L-IN-5 is a potent disruptor of telomeric silencing 1-like protein (**DOT1L**) inhibitor with an $IC_{50\ SPA\ DOT1L}$ of 0.17 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Dot1L-IN-6

Cat. No.: HY-135129

Dot1L-IN-6 is a potent disruptor of telomeric silencing 1-like protein (**DOT1L**) inhibitor with an $IC_{50\ SPA\ DOT1L}$ of 0.19 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Dot1L-IN-7

Cat. No.: HY-146724

Dot1L-IN-7 (compound 25) is a potent and selective disruptor of telomeric silencing 1-like protein (DOT1L) inhibitor with an IC50 of 1.0 μM. Dot1L-IN-7 selectively killed Mixed Lineage Leukemia (MLL)-AF9 without showing any effect on the growth of E2A-HLF cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

DS-437

Cat. No.: HY-124131

DS-437 is a dual **PRMT5/7** inhibitor (IC_{50}s of PRMT5/7=6 μM). DS-437 is selective for PRMT5 and PRMT7 over 29 other human protein-, DNA-, and RNA-methyltransferases. DS-437 is a S-adenosylmethionine (SAM)-competitive inhibitor of PRMT5.



Purity: 99.61%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

DW14800

Cat. No.: HY-128579

DW14800 is a protein arginine methyltransferase 5 (**PRMT5**) inhibitor, with an IC_{50} of 17 nM. DW14800 reduces H4R3me2s levels and enhances the transcription of HNF4α, but does not alter PRMT5 expression. Anti-cancer activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

E67-2

Cat. No.: HY-122746

E67-2, as the E67 derivative, is a low-toxicity, selective **KIAA1718** Jumonji domain inhibitor with an IC_{50} value of 3.4 μM. E67-2 selectively inhibits histone H3 lysine 9 (**H3K9**) Jumonji demethylase as well as histone H3 lysine 4 (**H3K4**) demethylase.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

EBI-2511

Cat. No.: HY-111418

EBI-2511 is a highly potent and orally active **EZH2** inhibitor, with an IC_{50} of 6 nM in Pfeffiera cell lines, respectively.



Purity: 99.41%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

EED ligand 1

Cat. No.: HY-132970

EED ligand 1 is a diverse, potent, and efficacious inhibitor that target the **EED subunit of the polycomb repressive complex 2 (PRC2)** methyltransferase.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EED226

Cat. No.: HY-101117

EED226 is a polycomb repressive complex 2 (**PRC2**) inhibitor, which binds to the K27me3-pocket on embryonic ectoderm development (**EED**) and shows strong antitumor activity in xenograft mice model. EED226 is a potent, selective, and orally bioavailable EED inhibitor.



Purity: 98.82%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

EEDi-5273

Cat. No.: HY-132922

EEDi-5273 is an exceptionally potent and orally efficacious **EED** inhibitor (IC_{50} = 0.2 nM) capable of achieving complete and persistent tumor regression.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EEDi-5285

Cat. No.: HY-136977

EEDi-5285 is an exceptionally potent and orally active **embryonic ectoderm development (EED)** inhibitor with an IC_{50} value of 0.2 nM for binds to the EED protein. EEDi-5285 has anti-cancer activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EHMT2-IN-1

Cat. No.: HY-111778

EHMT2-IN-1 is a potent **EHMT** inhibitor, with IC_{50}s of all <100 nM for EHMT1 peptide, EHMT2 peptide and cellular EHMT2. Used in the research of blood disorder or cancer.



Purity: 99.90%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

EHMT2-IN-2

Cat. No.: HY-111904

EHMT2-IN-2 is a potent **EHMT** inhibitor, with IC_{50}s of all <100 nM for EHMT1 peptide, EHMT2 peptide and cellular EHMT2. Used in the research of blood disease or cancer.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

EI1

(KB-145943)

Cat. No.: HY-15573

EI1 (KB-145943) is a potent and selective **EZH2** inhibitor with IC_{50} of 15 nM and 13 nM for EZH2 (WT) and EZH2 (Y641F), respectively.



Purity: 99.18%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

EML741

Cat. No.: HY-111544

EML741 is a histone lysine methyltransferase **G9a/GLP** inhibitor, with an IC_{50} of 23 nM, K_d of 1.13 μM for G9a. EML741 also inhibits DNMT1 (IC_{50}, 3.1 μM), with no effect on DNMT3a or DNMT3b. EML741 exhibits low cell toxicity, and is membrane permeable and blood-brain barrier penetrated.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EPZ-719

Cat. No.: HY-139626

EPZ-719 is a novel and potent **SETD2** inhibitor (IC_{50} = 0.005 μM) with a high selectivity over other histone methyltransferases.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

EPZ004777

Cat. No.: HY-15227

EPZ004777 is a potent, selective **DOT1L** inhibitor with an IC_{50} of 0.4 nM.



Purity: 98.24%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

EPZ004777 hydrochloride

Cat. No.: HY-15227A

EPZ004777 hydrochloride is a potent, selective **DOT1L** inhibitor with an IC_{50} of 0.4 nM.



Purity: 98.21%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

EPZ005687

Cat. No.: HY-15555

EPZ005687 is a potent and selective inhibitor of **EZH2** with K_i of 24 nM, and has 50-fold selectivity against EZH1 and 500-fold selectivity against 15 other protein methyltransferases.



Purity: 99.49%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

EPZ011989

Cat. No.: HY-16986

EPZ011989 is a potent, selective orally bioavailable EZH2 inhibitor with Ki < 3 nM for EZH2 wt and EZH2 Y646; 15-fold selectivity over EZH1 and >3000-fold selectivity over other HMTase.



Purity: 99.00%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

EPZ011989 trifluoroacetate

(EPZ-011989 trifluoroacetate)

Cat. No.: HY-16986A

EPZ011989 trifluoroacetate is a potent, selective orally bioavailable EZH2 inhibitor with Ki < 3 nM for EZH2 wt and EZH2 Y646; 15-fold selectivity over EZH1 and >3000-fold selectivity over other HMTase.



Purity: 98.71%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg

EPZ011989-d8

Cat. No.: HY-16986S

EPZ011989-d8 is the deuterium labeled EPZ011989. EPZ011989 is a potent, selective orally bioavailable EZH2 inhibitor with Ki < 3 nM for EZH2 wt and EZH2 Y646; 15-fold selectivity over EZH1 and >3000-fold selectivity over other HMTase.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EPZ015666

(GSK3235025)

Cat. No.: HY-12727

EPZ015666 (GSK3235025) is an orally available inhibitor of **PRMT5** with an IC_{50} of 22 nM.



Purity: 99.83%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

EPZ020411

Cat. No.: HY-12970

EPZ020411 is a potent and selective inhibitor of PRMT6 with IC50 of 10 nM, has 10 fold selectivity for PRMT6 over PRMT1 and PRMT8. IC50 value: 10 nM Target: PRMT6 in vitro: EPZ020411 inhibits methylation of PRMT6 substrates in cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EPZ020411 hydrochloride

Cat. No.: HY-12970A

EPZ020411 hydrochloride is a potent and selective inhibitor of **PRMT6** with IC_{50} of 10 nM, has >10 fold selectivity for PRMT6 over PRMT1 and PRMT8. IC50 value: 10 nM Target: PRMT6 in vitro: EPZ020411 inhibits methylation of PRMT6 substrates in cells.



Purity: 98.54%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

EPZ031686

Cat. No.: HY-19324

EPZ031686 is an orally available **SMYD3** inhibitor with an IC_{50} of 3 nM in cell-free assay.



Purity: 99.71%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

EZH2-IN-12

Cat. No.: HY-144330

EZH2-IN-12 (Compound 5) is a potent inhibitor of **EZH2**. EZH2-IN-12 has the potential for the research of central nervous system malignancies.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

EZH2-IN-2

Cat. No.: HY-A0298

EZH2-IN-2 is a **EZH2** inhibitor extracted from patent WO2018133795A1, Compound Example 69, with an IC_{50} of 64 nM. EZH2-IN-2 can be used for the research of cancer or precancerous condition related to EZH2 activity.



Purity: 98.06%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

EZH2-IN-4

Cat. No.: HY-139150

EZH2-IN-4 is an orally active, potent **EZH2** inhibitor with IC_{50}s of 0.923 nM and 2.65 nM against wild type (WT) 5-membered (5-mer) EZH2 and mutant 5-mer EZH2, respectively. EZH2-IN-4 has anti-cancer activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EZH2-IN-5

Cat. No.: HY-141566

EZH2-IN-5 is a potent **EZH2** inhibitor with IC_{50} values of 1.52 nM and 4.07 nM for wild-type and mutant Tyr641 EZH2, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EZH2-IN-6

Cat. No.: HY-145333

EZH2-IN-6 is an **EZH2** inhibitor with enhanced antitumor activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EZH2-IN-7

Cat. No.: HY-143616

EZH2-IN-7 is a potent inhibitor of **EZH2**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EZH2-IN-8

Cat. No.: HY-142951

EZH2-IN-8 is a potent inhibitor of **EZH2**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EZH2-IN-9

Cat. No.: HY-144094

EZH2-IN-9 is a potent inhibitor of **EZH2**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EZM 2302

Cat. No.: HY-111109

EZM 2302 is an inhibitor of coactivator-associated arginine methyltransferase 1 (**CARM1**) with an IC_{50} of 6nM.



Purity: 99.49%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

EZM0414

Cat. No.: HY-144858

EZM0414 is a potent, selective, orally bioavailable inhibitor of **SETD2** (IC_{50}=18 nM in SETD2 biochemical assay; IC_{50}=34 nM in cellular assay). EZM0414 can be used for the research of relapsed or refractory multiple myeloma and diffuse large B-cell lymphoma.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

FTX-6058

Cat. No.: HY-139400

FTX-6058 is a potent and orally active inhibitor of **Embryonic Ectoderm Development (EED)**. FTX-6058 can induce HbF protein expression in cell and murine models. FTX-6058 can be used for the research of select hemoglobinopathies, including sickle cell disease and β-thalassemia.



Purity: 99.97%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

FTX-6058 hydrochloride

Cat. No.: HY-139400A

FTX-6058 hydrochloride is a potent and orally active inhibitor of **Embryonic Ectoderm Development (EED)**. FTX-6058 hydrochloride can induce HbF protein expression in cell and murine models.



Purity: 99.83%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Furamidine

(DB75; NSC 305831)

Cat. No.: HY-110137A

Furamidine (DB75) is a selective **protein arginine methyltransferase 1 (PRMT1)** inhibitor with an IC_{50} of 9.4 μM. Furamidine is selective for **PRMT1** over PRMT5, PRMT6, and PRMT4 (CARM1) (IC_{50}s of 166 μM, 283 μM, and >400 μM, respectively).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Furamidine dihydrochloride

(DB75 dihydrochloride; NSC 305831 dihydrochloride)

Cat. No.: HY-110137

Furamidine dihydrochloride (DB75 dihydrochloride) is a selective **protein arginine methyltransferase 1 (PRMT1)** inhibitor with an IC_{50} of 9.4 μM.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg

Furamidine-d8

Cat. No.: HY-110137AS

Furamidine-d8 (DB75-d8) is the deuterium labeled Furamidine. Furamidine (DB75) is a selective **protein arginine methyltransferase 1 (PRMT1)** inhibitor with an IC_{50} of 9.4 μM.



Purity: >98%
Clinical Data:
Size: 1 mg, 10 mg

G9a-IN-1

Cat. No.: HY-44062

G9a-IN-1 (Compound 113) is a **G9a** protein inhibitor. G9A/EHMT2 is a nuclear histone lysine methyltransferase that catalyzes histone H3 lysine 9 dimethylation (H3K9me2), which is a reversible modification generally associated with transcriptional gene silencing.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Gambogenic acid

Cat. No.: HY-N5024

Gambogenic acid is an active ingredient in gamboge, with anticancer activity. Gambogenic acid acts as an effective inhibitor of **EZH2**, specifically and covalently binds to Cys668 within the EZH2-SET domain, and induces EZH2 ubiquitination.



Purity: 99.91%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

GNA002

Cat. No.: HY-101508

GNA002 is a highly potent, specific and covalent **EZH2** (Enhancer of zeste homolog 2) inhibitor with an IC_{50} of 1.1 μM.



Purity: 98.05%
Clinical Data: No Development Reported
Size: 5 mg

GSK126

(GSK2816126A)

Cat. No.: HY-13470

GSK126 (GSK2816126A) is a potent, highly selective inhibitor of **EZH2 methyltransferase** with an IC_{50} of 9.9 nM.



Purity: 99.98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

GSK2807 Trifluoroacetate

Cat. No.: HY-104009A

GSK2807 Trifluoroacetate is a potent, selective and SAM-competitive inhibitor of **SMYD3**, with a K_i of 14 nM and an IC_{50} of 130 nM.



Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

GSK3326595

(EPZ015938) Cat. No.: HY-101563

GSK3326595 (EPZ015938) is a potent, selective, reversible inhibitor of **protein arginine methyltransferase 5 (PRMT5)** with an IC_{50} of 6.2 nM.



Purity: 99.64%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

GSK3368715

(EPZ019997) Cat. No.: HY-128717

GSK3368715 (EPZ019997) is an orally active, reversible, and S-adenosyl-L-methionine (SAM) uncompetitive **type I protein arginine methyltransferases (PRMTs)** inhibitor (IC_{50}=3.1 nM (PRMT1), 48 nM (PRMT3), 1148 nM (PRMT4), 5.7 nM (PRMT6), 1.7 nM (PRMT8)).



Purity: >98%
Clinical Data: Phase 1
Size: 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

GSK3368715 dihydrochloride

(EPZ019997 dihydrochloride) Cat. No.: HY-128717A

GSK3368715 dihydrochloride (EPZ019997 dihydrochloride) is an orally active, reversible, and S-adenosyl-L-methionine (SAM) uncompetitive **type I protein arginine methyltransferases (PRMTs)** inhibitor (IC_{50}=3.1 nM (PRMT1), 48 nM (PRMT3), 1148 nM (PRMT4), 5.7 nM (PRMT6), 1.7...



Purity: 99.94%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

GSK343

Cat. No.: HY-13500

GSK343 is a highly potent and selective **EZH2** inhibitor with an IC_{50} of 4 nM.



Purity: 99.45%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

GSK503

Cat. No.: HY-12856

GSK503 is a potent and specific inhibitor of **EZH2** methyltransferase with K_i^{app} values of 3 to 27 nM.



Purity: 99.73%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

GSK591

(EPZ015866; GSK3203591) Cat. No.: HY-100235

GSK591 (EPZ015866) is a potent and selective inhibitor of **protein methyltransferase 5 (PRMT5)** with an IC_{50} of 4 nM.



Purity: 99.87%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

HLCL-61 hydrochloride

Cat. No.: HY-100025A

HLCL-61 hydrochloride is a first-in-class inhibitor of **protein arginine methyltransferase 5 (PRMT5)**.



Purity: 99.95%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

JNJ-64619178

(Onametostat) Cat. No.: HY-101564

JNJ-64619178 (Onametostat) is a selective, orally active and pseudo-irreversible **protein arginine methyltransferase 5 (PRMT5)** inhibitor with an IC_{50} of 0.14 nM. JNJ-64619178 has potent activity In lung cancer.



Purity: 99.79%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

JQEZ5

Cat. No.: HY-100846

JQEZ5 is a potent and selective **EZH2 lysine methyltransferase** inhibitor. JQEZ5 SAM-competitive inhibition of **polycomb repressive complex 2 (PRC2)** with an IC_{50} of 80 nM. JQEZ5 has anti-tumor effects.



Purity: 98.19%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

LEM-14

Cat. No.: HY-114340

LEM-14 is a potent **NSD2** inhibitor with an IC_{50} of 132 μM. LEM-14 has the potential for the research of multiple myeloma.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

LLY-283

Cat. No.: HY-107777

LLY-283 is a potent, selective and oral protein arginine methyltransferase 5 (**PRMT5**) inhibitor, with an IC_{50} of 22 nM and a K_d of 6 nM for PRMT5:MEP50 complex, and shows antitumor activity.



Purity: 99.04%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

LLY-507

Cat. No.: HY-19313

LLY-507 is a potent and selective inhibitor of protein-lysine methyltransferase **SMYD2**. LLY-507 potently inhibits the ability of SMYD2 to methylate p53 peptide with an IC_{50} <15 nM.



Purity: 98.47%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

MAK683

Cat. No.: HY-103663

MAK683 is an embryonic ectoderm development (**EED**) inhibitor extracted from patent US20160176882 A1, compound example 2. MAK683 exhibits IC_{50}s of 59, 89, 26 nM in EED Alphascreen binding, LC-MS and ELISA assay.



Purity: 99.27%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

MAK683 hydrochloride

Cat. No.: HY-103663A

MAK683 hydrochloride is an embryonic ectoderm development (**EED**) inhibitor extracted from patent US20160176882 A1, compound example 2. MAK683 exhibits IC_{50}s of 59, 89, 26 nM in EED Alphascreen binding, LC-MS and ELISA assay.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MAK683-CH2CH2COOH

Cat. No.: HY-130815

MAK683-CH2CH2COOH binds to EED (embryonic ectoderm development protein). MAK683-CH2CH2COOH and a VHL ligand for the E3 ubiquitin ligase have been used to design PROTAC EED degrader-1 (HY-130614) and PROTAC EED degrader-2 (HY-130615).



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

MC4355

Cat. No.: HY-144905

MC4355 is a dual inhibitor of **EZH2** and histone deacetylase **(HDAC)**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Metoprine

(BW 197U)

Cat. No.: HY-129441

Metoprine (BW 197U) is a potent **histamine N-methyltransferase (HMT)** inhibitor. Metoprine, a diaminopyrimidine derivative, can cross the blood-brain barrier and increase brain histamine levels by inhibiting HMT. Metoprine is an **antifolate** and antitumor agent.



Purity: 99.04%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

MM-102

(HMTase Inhibitor IX)

Cat. No.: HY-12220

MM-102 (HMTase Inhibitor IX) is a potent **WDR5/MLL** interaction inhibitor, achieves IC_{50}= 2.4 nM with an estimated K_i< 1 nM in WDR5 binding assay, which is >200 times more potent than the ARA peptide.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MM-102 TFA

(HMTase Inhibitor IX TFA)

Cat. No.: HY-12220A

MM-102 TFA (HMTase Inhibitor IX TFA) is a potent WDR5/MLL interaction inhibitor, achieves IC50 = 2.4 nM with an estimated Ki < 1 nM in WDR5 binding assay, which is >200 times more potent than the ARA peptide.



Purity: 99.77%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg

MM-401

Cat. No.: HY-19554

MM-401 is a potent inhibitor for the **MLL1-WDR5** interaction with the IC_{50} of 0.9 nM in disrupting WDR5-MLL1 interaction. MM-401 maintains high binding affinity to WDR5 (K_i<1 nM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MM-589

Cat. No.: HY-100869

MM-589 is a potent inhibitor of **WD repeat domain 5 (WDR5) and mixed lineage leukemia (MLL)** protein-protein interaction. MM-589 binds to WDR5 with an IC_{50} of 0.90 nM and inhibits the MLL H3K4 methyltransferase activity with an IC_{50} of 12.7 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MM-589 TFA

Cat. No.: HY-100869A

MM-589 TFA is a potent inhibitor of **WD repeat domain 5 (WDR5) and mixed lineage leukemia (MLL)** protein-protein interaction. MM-589 binds to WDR5 with an IC_{50} of 0.90 nM and inhibits the MLL H3K4 methyltransferase activity with an IC_{50} of 12.7 nM.



Purity: 98.76%
Clinical Data: No Development Reported
Size: 1 mg, 2 mg

MR837

Cat. No.: HY-138283

MR837 is an inhibitor of **NSD2-PWWP1**. MR837 can bind with human nuclear receptor binding SET domain protein 2 (PWWP domain).



Purity: 99.40%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

MRK-740

Cat. No.: HY-114209

MRK-740 is a potent, selective and substrate-competitive **PRDM9 histone methyltransferase** inhibitor with an IC_{50} of 80nM. MRK-740 is more selective for **PRDM9** than other histone methyltransferases and other non-epigenetic targets.



Purity: 99.21%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

MRTX-1719

Cat. No.: HY-139611

MRTX-1719 is a potent first-in-class selective inhibitor of the **PRMT5/MTA** complex, with an IC_{50} of less than 10 nM in PRMT5/MTA $MTAP^{DEL}$ SDMA cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

MRTX9768

Cat. No.: HY-138684

MRTX9768 is a potent, selective, orally active, first-in-class **PRMT5-MTA complex** inhibitor.



Purity: 99.60%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg

MRTX9768 hydrochloride

Cat. No.: HY-138684A

MRTX9768 hydrochloride is a potent, selective, orally active, first-in-class **PRMT5-MTA complex** inhibitor.



Purity: 99.68%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg

MS0124

Cat. No.: HY-120444

MS0124 is a potent selective **G9a-like protein (GLP)** inhibitor with IC_{50} values of 13±4 nM and 440±63 nM for GLP and G9a,respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MS023

Cat. No.: HY-19615

MS023 is a potent, selective, and cell-active inhibitor of human **type I protein arginine methyltransferases (PRMTs)** inhibitor, with IC_{50}s of 30, 119, 83, 4 and 5 nM for **PRMT1**, **PRMT3**, **PRMT4**, **PRMT6**, and **PRMT8**, respectively.



Purity: 99.12%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

MS023 dihydrochloride

Cat. No.: HY-19615B

MS023 dihydrochloride is a potent, selective, and cell-active inhibitor of human **type I protein arginine methyltransferases (PRMTs)** inhibitor, with IC_{50}s of 30, 119, 83, 4 and 5 nM for **PRMT1**, **PRMT3**, **PRMT4**, **PRMT6**, and **PRMT8**, respectively.



Purity: 99.78%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

MS049

Cat. No.: HY-100360

MS049 is a potent, selective, and cell-active dual inhibitor of **PRMT4** and **PRMT6** with IC_{50}s of 34 nM and 43 nM, respectively. MS049 reduces levels of Med12me2a and H3R2me2a in HEK293 cells. MS049 is not toxic and does not affect the growth of HEK293 cells.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

MS049 dihydrochloride

Cat. No.: HY-100360A

MS049 dihydrochloride is a potent, selective, and cell-active dual inhibitor of **PRMT4** and **PRMT6** with IC_{50}s of 34 nM and 43 nM, respectively. MS049 dihydrochloride reduces levels of Med12me2a and H3R2me2a in HEK293 cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MS117

Cat. No.: HY-133740

MS117 is a first-in-class and cell-active irreversible **protein arginine methyltransforase 6 (PRMT6)** covalent inhibitor, with an IC_{50} of 18 nM.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

MS1943

Cat. No.: HY-133129

MS1943 is a first-in-class, orally bioavailable **EZH2** selective degrader, with an IC_{50} of 120 nM. MS1943 significantly reduces EZH2 protein levels in numerous triple-negative breast cancer (TNBC) and other cancer and noncancerous cell lines.



Purity: 98.18%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

MS33

Cat. No.: HY-141797

MS33 is a potent **WDR5** degrader, with K_ds of 870 nM and 120 nM for **VCB** and **WDR5**, respectively. MS33 induces WDR5 degradation in an E3 ligase VHL, and proteasome-dependent manner. MS33 can be used for the research of acute myeloid leukemia.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MS37452

Cat. No.: HY-119344

MS37452 is a potent inhibitor of **CBX7** chromodomain binding to **H3K27me3**, with a K_d of 27.7 μM. MS37452 can derepress transcription of polycomb repressive complex target gene p16/CDKN2A by displacing CBX7 binding to the INK4A/ARF locus in prostate cancer cells.



Purity: 99.22%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

MS67

Cat. No.: HY-141796

MS67 is a potent and selective **WD40 repeat domain protein 5 (WDR5)** degrader with a K_d of 63 nM. MS67 is inactive against other protein methyltransferases, kinases, GPCRs, ion channels, and transporters. MS67 shows potent acticancer effects.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

MU1656

Cat. No.: HY-145813

MU1656 is a potent and selective inhibitor of **histone methyltransferase DOT1L**, with an IC_{50} of 2 nM. MU1656 can be used for the research of hematological malignancies.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

NSC 663284

(DA-3003-1)

Cat. No.: HY-100034

NSC 663284 (DA-3003-1) is a potent, cell-permeable, and irreversible **Cdc25 dual specificity phosphatase** inhibitor, has an IC_{50} for Cdc25B2 of 0.21 μM.



Purity: 99.87%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

NSC745885

Cat. No.: HY-119198

NSC745885 an effective **anti-tumor** agent, shows selective toxicity against multiple cancer cell lines but not normal cells. NSC745885 is an effective down-regulator of **EZH2** via proteasome-mediated degradation.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

NV03

Cat. No.: HY-125292

NV03 is a potent and selective antagonist of **UHRF1** (Ubiquitin-like with PHD and RING finger domains 1)- **H3K9me3** interaction by binding to UHRF1 tandem tudor domain, with a K_d of 2.4 μM. NV03 has anticancer activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

OICR-9429

Cat. No.: HY-16993

OICR-9429 is a novel small-molecule antagonist of the Wdr5-MLL interaction with IC50 of 5 uM. inhibit proliferation and induce differentiation . target: Wdr5 IC 50: 5 uM In vitro: OICR-9429 inhibit proliferation and induce differentiation in p30-expressing human AML cells.



Purity: 99.91%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

OTS186935

Cat. No.: HY-122181

OTS186935 is a potent protein methyltransferase **SUV39H2** inhibitor with an **IC_{50}** of 6.49 nM. OTS186935 shows significant inhibition of tumor growth in mouse xenograft models without any detectable toxicity. OTS193320 regulates the production of γ-H2AX in cancer cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

OTS186935 hydrochloride

Cat. No.: HY-122181B

OTS186935 hydrochloride is a potent protein methyltransferase **SUV39H2** inhibitor with an **IC_{50}** of 6.49 nM. OTS186935 hydrochloride shows significant inhibition of tumor growth in mouse xenograft models without any detectable toxicity.



Purity: 99.86%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

OTS186935 trihydrochloride

Cat. No.: HY-122181A

OTS186935 trihydrochloride is a protein methyltransferase **SUV39H2** inhibitor with an **IC_{50}** of 6.49 nM. OTS186935 trihydrochloride shows significant inhibition of tumor growth in mouse xenograft models without any detectable toxicity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PARP/EZH2-IN-1

Cat. No.: HY-132885

PARP/EZH2-IN-1 is a first-in-class dual **PARP** (**IC_{50}** 6.87 nM) and **EZH2** (**IC_{50}** 36.51 nM) inhibitor for triple-negative breast cancer with wild-type BRCA.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PF-06726304

Cat. No.: HY-103682

PF-06726304 is a potent and selective **EZH2** inhibitor. PF-06726304 inhibits wild-type and Y641N mutant EZH2 with **K_i**s of 0.7 and 3.0 nM, respectively. PF-06726304 displays robust antitumor growth activity.



Purity: 99.64%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

PF-06726304 acetate

Cat. No.: HY-103682A

PF-06726304 acetate is a potent and selective **EZH2** inhibitor. PF-06726304 acetate inhibits wild-type and Y641N mutant EZH2 with **K_i**s of 0.7 and 3.0 nM, respectively. PF-06726304 acetate displays robust antitumor growth activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PFI-2

((R)-PFI-2)

Cat. No.: HY-18627

PFI-2 is a a first-in-class, potent, highly selective, and cell-active inhibitor of the methyltransferase activity of SETD7 with IC50 of 2 nM, 500 fold active than (S)-PFI-2.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PFI-2 hydrochloride

((R)-PFI-2 hydrochloride)

Cat. No.: HY-18627A

PFI-2 hydrochloride is a a first-in-class, potent, highly selective, and cell-active inhibitor of the methyltransferase activity of SETD7 with IC50 of 2 nM, 500 fold active than (S)-PFI-2.



Purity: 99.80%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

Pinometostat

(EPZ-5676)

Cat. No.: HY-15593

Pinometostat (EPZ-5676) is a potent **DOT1L histone methyltransferase** inhibitor with a K_i of 80 pM.



Purity: 99.99%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

PR5-LL-CM01

Cat. No.: HY-109963

PR5-LL-CM01 is a potent protein arginine methyltransferase 5 **(PRMT5)** inhibitor (IC_{50}= 7.5 μM). Anti-tumor activies.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PRMT1-IN-1

Cat. No.: HY-115758

PRMT1-IN-1 is a PRMT1 inhibitor.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PRMT5-IN-1

Cat. No.: HY-126256

PRMT5 IN-1, a hemiaminal, is a covalent **protein arginine methyltransferase 5 (PRMT5)** inhibitor with an IC_{50} of 11 nM for PRMT5/MEP50. PRMT5 IN-1 can be converted to aldehydes and react with C449 to form covalent adducts under physiological conditions.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

PRMT5-IN-10

Cat. No.: HY-139823

PRMT5-IN-10 has promising structure-dependent inhibition of the protein methyltransferase **PRMT5:MEP50** complex.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PRMT5-IN-11

Cat. No.: HY-139823A

PRMT5-IN-11 is a promising structure-dependent inhibition of the protein methyltransferase **PRMT5:MEP50** complex in the (sub)micromolar range.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PRMT5-IN-12

Cat. No.: HY-141874

PRMT5-IN-12 shows remarkable inhibitory activity on **PRMT5**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PRMT5-IN-13

Cat. No.: HY-141875

PRMT5-IN-13 is a selective inhibitor of **protein arginine methyltransferase 5 (prmt5)**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PRMT5-IN-14

Cat. No.: HY-141876

PRMT5-IN-14 is a **PRMT5** inhibitor to treat cancer, sickle cell, and hereditary persistence of foetal hemoglobin (HPFH) mutations.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PRMT5-IN-15

Cat. No.: HY-142211

PRMT5-IN-15 is a **PRMT5** inhibitor with an IC_{50} value of 0.84 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PRMT5-IN-2

Cat. No.: HY-112165

PRMT5-IN-2 is a **rotein arginine methyltransferase 5 (PRMT5)** inhibitor extracted from patent WO2018130840A1, compound 3.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PRMT5-IN-3

Cat. No.: HY-131493

PRMT5-IN-3 is a **PRMT5** inhibitor that exhibits synthetic lethality to tumor cells but produce few side effects combined with DNA damaging agents.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PRMT5-IN-4

Cat. No.: HY-134883

PRMT5-IN-4 (compound AAA-1) is a **PRMT5** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PRMT5-IN-9

Cat. No.: HY-132937

PRMT5-IN-9 is a novel PRMT5 inhibitor for treating cancer, with an IC_{50} of 0.01 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PROTAC EED degrader-1

Cat. No.: HY-130614

PROTAC EED degrader-1 is a **von Hippel-Lindau**-based **PROTAC** targeting **EED** with a pK_D of 9.02.
PROTAC EED degrader-1 is a polycomb repressive complex 2 (**PRC2**) inhibitor (pIC_{50}=8.17) targeting the EED subunit.



Purity: 99.56%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

PROTAC EED degrader-2

Cat. No.: HY-130615

PROTAC EED degrader-2 is a **von Hippel-Lindau**-based **PROTAC** targeting **EED** with a pK_D of 9.27.
PROTAC EED degrader-2 is a polycomb repressive complex 2 (**PRC2**) inhibitor (pIC_{50}=8.11) targeting the EED subunit.



Purity: 98.64%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

SETD2-IN-1 TFA

Cat. No.: HY-136328

SETD2-IN-1 TFA is a potent, selective and orally active inhibitor of **SETD2** which is a human histone methyltransferase. SETD2-IN-1 TFA has anti-proliferative effects.



Purity: 99.42%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

SETDB1-TTD-IN-1

Cat. No.: HY-141539

SETDB1-TTD-IN-1 is a potent, selective and endogenous binder competitive inhibitor of **SET domain bifurcated protein 1 tandem tudor domain (SETDB1-TTD)**, with a K_d of 88 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

SETDB1-TTD-IN-1 TFA

Cat. No.: HY-141539A

SETDB1-TTD-IN-1 TFA is a potent, selective and endogenous binder competitive inhibitor of **SET domain bifurcated protein 1 tandem tudor domain (SETDB1-TTD)**, with a K_d of 88 nM.



Purity: 98.79%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SGC0946

Cat. No.: HY-15650

SGC0946 is a highly potent and selective DOT1L methyltransferase inhibitor with IC50 of 0.3 nM; selectively kill mixed lineage leukaemia cells.



Purity: 99.68%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

SGC2085

Cat. No.: HY-100565

SGC2085 is a potent and selective coactivator associated arginine methyltransferase 1 (**CARM1**) inhibitor with an IC_{50} of 50 nM.



Purity: 99.45%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

SGC3027

Cat. No.: HY-112445

SGC3027 is a **histone methyltransferase** inhibitor. SGC3027 is the first potent, selective and cell active chemical probe for **PRMT7**.



Purity: 98.52%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

SGC707

Cat. No.: HY-19715

SGC707 is a first-in-class PRMT3 chemical probe which is a potent, selective, and cell-active allosteric inhibitor of PRMT3 with IC50 of 31 nM. IC50 value: 31 nM Target: PRMT3 in vitro: SGC707 is the first PRMT3 chemical probe.



Purity: 99.39%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 500 mg

Sinefungin

(Adenosyl-Ornithine; A-9145; Antibiotic 32232RP)

Cat. No.: HY-101938

Sinefungin is a potent inhibitor of virion **mRNA(guanine-7-)-methyltransferase, mRNA(nucleoside-2'-)-methyltransferase**, and viral multiplication. Sinefungin, a **SET7/9** inhibitor, ameliorates renal fibrosis by inhibiting H3K4 methylation.



Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 1 mg

SMYD2-IN-1

Cat. No.: HY-111810

SMYD2-IN-1 is a **SMYD2** inhibitor extracted from patent WO2016166186A1, compound example 1.1, has an IC_{50} of 4.45 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SMYD3-IN-1

Cat. No.: HY-128352

SMYD3-IN-1 (compound 29) is an irreversible and selective inhibitor of **SMYD3 (SET and MYND domain containing 3)**, with an IC_{50} of 11.7 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

SW2_110A

Cat. No.: HY-141716

SW2_110A is a selective **chromobox 8 chromodomain (CBX8 ChD)** inhibitor with a K_d of 800 nM. SW2_110A shows minimal 5-fold selectivity for CBX8 ChD over all other CBX paralogs in vitro.



Purity: 99.16%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Tazemetostat

(EPZ-6438; E-7438)

Cat. No.: HY-13803

Tazemetostat (EPZ-6438) is a potent, selective and orally available **EZH2** inhibitor. Tazemetostat (EPZ-6438) inhibits the activity of human polycomb repressive complex 2 (PRC2)-containing wild-type EZH2 with a K_i value of 2.5 nM.



Purity: 99.93%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Tazemetostat hydrobromide

(EPZ-6438 hydrobromide; E-7438 hydrobromide)

Cat. No.: HY-13803C

Tazemetostat hydrobromide (EPZ-6438 hydrobromide) is a potent, selective and orally available **EZH2** inhibitor. Tazemetostat hydrobromide inhibits the activity of human polycomb repressive complex 2 (PRC2)-containing wild-type EZH2 with a K_i value of 2.5 nM.



Purity: 99.61%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Tazemetostat trihydrochloride

(EPZ-6438 trihydrochloride; E-7438 trihydrochloride)

Cat. No.: HY-13803A

Tazemetostat trihydrochloride (EPZ-6438 trihydrochloride) is a potent, selective and orally available **EZH2** inhibitor. Tazemetostat trihydrochloride inhibits the activity of human polycomb repressive complex 2 (PRC2)-containing wild-type EZH2 with a K_i of 2.5 nM.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Tazemetostat-d8

(EPZ-6438-d8; E-7438-d8)

Cat. No.: HY-13803S

Tazemetostat-d8 is deuterium labeled Tazemetostat. Tazemetostat (EPZ-6438) is a potent, selective and orally available EZH2 inhibitor. Tazemetostat (EPZ-6438) inhibits the activity of human polycomb repressive complex 2 (PRC2)-containing wild-type EZH2 with a Ki value of 2.5 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TC-E 5003

Cat. No.: HY-107574

TC-E 5003 is a selective **PRMT1** inhibitor with an IC_{50} of 1.5 μM against hPRMT1. TC-E 5003 has anti-inflammatory properties in TLR4 signaling.



Purity: 99.45%
Clinical Data: No Development Reported
Size: 25 mg, 50 mg, 100 mg

TM2-115

Cat. No.: HY-121493

TM2-115 inhibits malaria parasite histone methyltransferases, resulting in rapid and irreversible parasite death.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TP-064

Cat. No.: HY-114965

TP-064 is a potent and selective **proteinarginine methyltransferase 4 (PRMT4; CARM1)** inhibitor (IC_{50} <10 nM). TP-064 inhibits dimethylation of BAF155 (IC_{50} of 340 nM) and MED12 (IC_{50} of 43 nM). TP-064 is inactive against the other family members except for PRMT6 (IC_{50} of 1.3 μM).



Purity: 98.35%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg

UNC 0631

Cat. No.: HY-13808

UNC 0631 is a potent **histone methyltransferase G9a** inhibitor with an IC_{50} of 4 nM. UNC 0631 potently reduces **H3K9me2** levels in MDA-MB-231 cells with an IC_{50} of 25 nM.



Purity: 99.35%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

UNC0224

Cat. No.: HY-10929

UNC0224 is a potent and selective **histone methyltransferase G9a** inhibitor with a K_i of 2.6 nM, an IC_{50} of 15 nM and a K_d of 23 nM. UNC0224 also potently inhibits b>GLP with assay-dependent IC_{50} values of 20-58 nM.



Purity: 99.31%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

UNC0321

Cat. No.: HY-10930

UNC0321 is a potent and selective **histone methyltransferase G9a** inhibitor with a K_i of 63 pM and with assay-dependent IC_{50} values of 6-9 nM. UNC0321 also inhibits **GLP** with assay-dependent IC_{50} values of 15-23 nM. UNC0321 is inactive against SET7/9, SET8/PreSET7, PRMT3 and JMJD2E.



Purity: 99.43%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

UNC0379

Cat. No.: HY-12335

UNC0379 is a selective, substrate-competitive inhibitor of **lysine methyltransferase SETD8** (**KMT5A**) with an IC_{50} of 7.3 μM; selective over 15 other methyltransferases.



Purity: 99.75%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

UNC0379 TFA

Cat. No.: HY-12335A

UNC0379 TFA is a selective, substrate-competitive inhibitor of **lysine methyltransferase SETD8** (**KMT5A**) with an IC_{50} of 7.3 μM; selective over 15 other methyltransferases.



Purity: 99.91%
Clinical Data: No Development Reported
Size: 2 mg, 5 mg

UNC0638

Cat. No.: HY-15273

UNC0638 selectively inhibits **G9a** and **GLP histone methyltransferase** activity with IC_{50}s of less than 15 nM and 19 nM, respectively. UNC0638 has anti-**FMDV (foot-and-mouth disease virus)** and anti-**VSV (vesicular stomatitis virus)** activities.



Purity: 99.73%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

UNC0642

Cat. No.: HY-13980

UNC0642 is a potent and selective lysine methyltransferases **G9a** and **GLP** inhibitor, with an IC_{50} of <2.5 nM for **G9a**.



Purity: 99.86%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

UNC0646

Cat. No.: HY-13807

UNC0646 is a potent and selective **histone methyltransferase G9a** inhibitor with an IC_{50} of 6 nM. UNC0646 is also a potent **GLP** inhibitor (IC_{50} <15 nM) and highly selective for **G9a/GLP** over SETD7, SUV39H2, SETD8 and PRMT3.



Purity: 99.82%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

UNC1215

Cat. No.: HY-15649

UNC1215 is a potent and selective inhibitor for the **methyllysine (Kme) reading domain** function of **L3MBTL3** with a K_d value of 120 nM and an IC_{50} of 40 nM. UNC1215 has the potential to treat malignant brain tumor.



Purity: 98.47%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

UNC1999

Cat. No.: HY-15646

UNC1999 is a SAM-competitive, potent and selective inhibitor of **EZH2/1** with IC_{50}s of <10 nM and 45 nM, repectively.



Purity: 99.85%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

UNC2327

Cat. No.: HY-110158

UNC2327 is an allosteric inhibitor of protein arginine methyltransferase 3 (**PRMT3**).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

UNC2399

Cat. No.: HY-136188

UNC2399, a biotinylated UNC1999, is a selective **EZH2** degrader, maintaining high in vitro potency for EZH2, with an IC_{50} of 17 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

UNC2400

Cat. No.: HY-12845

UNC2400 is a close analog of UNC1999 with >1,000-fold lower potency than UNC1999 as a negative control for cell-based studies.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

UNC3866

Cat. No.: HY-100832

UNC3866 is a potent antagonist of the **CBX7**-H3 interaction as determined by AlphaScreen (IC_{50}=66±1.2 nM) and is more than 100-fold selective for CBX7 over the other nine members of this methyl-lysine (Kme) reader panel.



Purity: 97.14%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

UNC4976

Cat. No.: HY-126327

UNC4976 is a positive allosteric modulator (PAM) peptidomimetic of CBX7 chromodomain binding to nucleic acids. UNC4976 simultaneously antagonizes H3K27me3-specific recruitment of CBX7 to target genes while increasing non-specific binding to DNA and RNA.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

UNC6852

Cat. No.: HY-130708

UNC6852 is a selective **polycomb repressive complex 2 (PRC2)** degrader based on PROTAC and contains an **EED** (embryonic ectoderm development) ligand and a **von Hippel-Lindau** ligand, with an IC_{50} of 247 nM for EED.



Purity: 98.68%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

UNC6934

Cat. No.: HY-145103

UNC6934, a chemical probe targeting the PWWP domain, alters **NSD2** nucleolar localization.



Purity: 98.51%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Valemetostat

(DS-3201)

Cat. No.: HY-109108

Valemetostat (DS-3201) is a first-in-class **EZH1/2** dual inhibitor, used in the research of relapsed/refractory peripheral T-cell lymphoma.



Purity: 99.65%
Clinical Data: Launched
Size: 5 mg, 10 mg

Valemetostat tosylate

(DS-3201 tosylate)

Cat. No.: HY-109108A

Valemetostat tosylate (DS-3201 tosylate), a first-in-class **EZH1/2** dual inhibitor, has the potential in the research of relapsed/refractory peripheral T-cell lymphoma.



Purity: 98.14%
Clinical Data: Launched
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

WDR5-0103

(WD-Repeat Protein 5-0103)

Cat. No.: HY-19347

WDR5-0103 is a potent and selective WD repeat-containing protein 5 (WDR5) antagonist with Kd of 450 nM.



Purity: 98.11%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

WDR5-0103-d3

(WD-Repeat Protein 5-0103-d3)

Cat. No.: HY-19347S

WDR5-0103-d3 (WD-Repeat Protein 5-0103-d3) is the deuterium labeled WDR5-0103. WDR5-0103 is a potent and selective WD repeat-containing protein 5 (WDR5) antagonist with K_d of 450 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

WDR5-IN-1

Cat. No.: HY-133121

WDR5-IN-1 is a potent and selective **WD repeat domain 5 (WDR5)** inhibitor, with a K_d of <0.02 nM. WDR5-IN-1 inhibits MLL1 histone methyltransferase (HMT) activity with an IC_{50} of 2.2 nM.



Purity: 98.71%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

WDR5-IN-4

Cat. No.: HY-111753

WDR5-IN-4 is an inhibitor of the WIN site of chromatin-associated WD repeat-containing protein 5 (**WDR5**), with a K_d of 0.1 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

WDR5-IN-4 TFA

Cat. No.: HY-111753A

WDR5-IN-4 TFA is an inhibitor of the WIN site of chromatin-associated WD repeat-containing protein 5 (**WDR5**), with a K_d of 0.1 nM.



Purity: 98.43%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

XY1

Cat. No.: HY-19714

XY1 is a very close analogue of SGC707 (a potent, selective, and non-competitive inhibitor of PRMT3 with IC50 of 31 nM), but XY1 is completely inactive.



Purity: 99.10%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

YM281

Cat. No.: HY-145762

YM281 is a potent **EZH2** inhibitor. YM281 induces cell **apoptosis** and cell cycle arrest at the G0/G1 phase. YM281 shows antitumor effects in vivo. YM281 has the potential for the research of lymphoma.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

YM458

Cat. No.: HY-146999

YM458 is a potent **EZH2** and **BRD4** dual inhibitor with **IC_{50}**s of 490 nM and 34 nM, respectively. YM458 inhibits cell proliferation and colony formation and induces cell cycle arrest and **apoptosis** in solid cancer cells. YM458 can be used for researching anticancer.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ZLD1039

Cat. No.: HY-116804

ZLD1039 is a potent, highly selective, and orally bioavailable **EZH2** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg